The landscape of metabolic research has been completely redefined by the development of incretin mimetics. Understanding the difference between single, dual, and triple agonists is crucial for accurate in-vitro modelling.
Single Agonists (GLP-1)
Semaglutide is the most highly researched single agonist, targeting exclusively the Glucagon-Like Peptide-1 (GLP-1) receptor. In laboratory models, GLP-1 activation delays gastric emptying and stimulates glucose-dependent insulin secretion.
Dual Agonists (GLP-1 / GIP)
Tirzepatide introduced the concept of "twin-cretin" research. By agonizing both the GLP-1 and the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors simultaneously, researchers observed synergistic effects on metabolic regulation that vastly outpaced single agonists in cellular assays.
Triple Agonists (GLP-1 / GIP / GCGR)
Retatrutide (RETA) represents the bleeding edge of metabolic research. It agonizes GLP-1, GIP, and the Glucagon Receptor (GCGR). The addition of glucagon receptor agonism directly increases energy expenditure in hepatic models, creating a tri-modal metabolic response.
Purivo Biolabs supplies analytically characterized Reference Materials for all three generations of these metabolic compounds to verified UK institutions.
